Volition Advances Nu.Q® NETs Platform Towards Commercialization

Consistent international data positions Nu.Q® NETs as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product.

It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.

Mr. Gael Forterre , Chief Commercial Officer, Volition commented: Dr Andrew Retter highlighting the significant clinical and scientific evidence amassed for Nu.Q® NETs "We are in active discussions with several large diagnostic companies to accelerate the development of Nu.Q® NETs and believe the potential use cases represent a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $3.8 billion."

Professor Djillali Annane , Intensive Care Department, IHU SEPSIS, Raymond Poincaré Hospital (AP-HP) commented: "This is the first time I have seen so much data , so quickly, on a sepsis biomarker with consistent findings.

The consistency of data from different teams, across different countries and across different types of sepsis is extremely reassuring.

"Results show that Nu.Q® H3.1 accurately distinguishes sepsis from non-infectious systemic inflammation, is highly correlated with disease severity, and provides excellent prognostic utility for outcomes such as organ failure and mortality 1-4 .

Nu.Q® H3.1 provides new and additional information above standard organ failure scores such as APACHE II and SOFA scores 1-4 .

"I believe that using the Nu.Q® NETs test to measure elevated H3.1 nucleosome levels as a " treatable trait " in sepsis management could be a game changer in modifying a patient's trajectory.

Introducing Nu.Q® NETs into hospitals could lead to new ways of treating sepsis, improving patient survival and the quality of life of survivors."

Dr Andrew Retter , Critical Care Lead and Medical Consultant, Volition, said: "We have amassed a significant body of both scientific and clinical evidence to support the use of Volition's Nu.Q® NETs assay in diseases associated with NETosis.

The majority of these papers have now been peer reviewed and published.

"Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test to detect diseases associated with NETosis.

Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage and, in severe cases, sepsis, organ failure, and death.

Filipini D, et al. (2025). Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failure https://doi.org/10.1186/s13054-025-05415-6 Neumann et al, MEDRXIV Haem Rahimi M, et al. (2023) Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock. Ann Intensive Care. doi: 10.1186/s13613-023-01204-y Morimont, L., et al. (2022). NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study. Biomolecules. doi: 10.3390/biom12081038

About Volition Volition is a multi-national company focused on advancing the science of epigenetics.

Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseas...